ORG Partners LLC Purchases New Stake in Novo Nordisk A/S (NYSE:NVO)

ORG Partners LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,966 shares of the company’s stock, valued at approximately $251,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Folketrygdfondet grew its position in Novo Nordisk A/S by 1.4% in the first quarter. Folketrygdfondet now owns 8,756,034 shares of the company’s stock valued at $1,124,275,000 after acquiring an additional 124,770 shares during the last quarter. Capital International Investors grew its holdings in shares of Novo Nordisk A/S by 22.3% during the fourth quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock worth $736,121,000 after purchasing an additional 1,297,536 shares during the last quarter. Raymond James & Associates grew its holdings in shares of Novo Nordisk A/S by 12.1% during the first quarter. Raymond James & Associates now owns 3,143,731 shares of the company’s stock worth $403,655,000 after purchasing an additional 340,549 shares during the last quarter. Natixis Advisors L.P. grew its holdings in shares of Novo Nordisk A/S by 1.8% during the fourth quarter. Natixis Advisors L.P. now owns 3,052,406 shares of the company’s stock worth $315,770,000 after purchasing an additional 55,333 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in Novo Nordisk A/S by 4.0% in the fourth quarter. Clearbridge Investments LLC now owns 2,314,261 shares of the company’s stock valued at $239,410,000 after acquiring an additional 89,152 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO traded up $2.30 during trading on Friday, reaching $142.09. The company’s stock had a trading volume of 2,690,023 shares, compared to its average volume of 4,434,837. The firm has a market cap of $637.63 billion, a price-to-earnings ratio of 49.16, a price-to-earnings-growth ratio of 1.42 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The firm has a 50 day moving average of $137.68 and a 200-day moving average of $125.97. Novo Nordisk A/S has a 12 month low of $77.96 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. The firm had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Research analysts expect that Novo Nordisk A/S will post 3.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Argus upped their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a report on Monday, June 10th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, July 1st. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $145.67.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.